Sucralfate

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Sucralfate
Accession Number
DB00364  (APRD01238)
Type
Small Molecule
Groups
Approved
Description

Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers Label, gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia 2. It is considered a cytoprotective agent, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances 2,13.

Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form 11,12.

Structure
Thumb
Synonyms
  • Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum
  • Sucralfat
  • Sucralfate
  • Sucralfato
  • Sucralfatum
External IDs
CGA-6J / OS 202
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CarafateSuspension1 g/10mLOralAllergan1993-12-16Not applicableUs
CarafateSuspension1 g/10mLOralAtlantic Biologicals Corps.1993-12-16Not applicableUs
CarafateTablet1 g/1OralAllergan, Inc.1981-10-30Not applicableUs
CarafateSuspension1 g/10mLOralPhysicians Total Care, Inc.1996-03-12Not applicableUs
SucralfateSuspension1 g/10mLOralVistapharm, Inc.2012-08-16Not applicableUs
SucralfateTablet1 g/1OralRemedy Repack2009-06-182017-02-24Us
SucralfateSuspension1 g/10mLOralPhysicians Total Care, Inc.2005-05-24Not applicableUs
SucralfateSuspension1 g/10mLOralPharmaceutical Associates, Inc.2009-11-19Not applicableUs
SucralfateTablet1 g/1OralRemedy Repack2010-05-202010-12-10Us
SucralfateTablet1 g/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs00591 0780 05 nlmimage10 b71d5bfa
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-sucralfate - Tab 1gTablet1 gOralApotex Corporation1994-12-31Not applicableCanada
Dom-sucralfateTablet1000 mgOralDominion Pharmacal1999-09-152016-10-25Canada
Nu-sucralfate - Tab 1gmTablet1 gOralNu Pharm Inc1994-12-312012-09-04Canada
PMS-sucralfateTablet1000 mgOralPharmascience Inc1999-02-23Not applicableCanada
SucralfateTablet1 g/1OralCardinal Health2011-05-272015-05-31Us
SucralfateTablet1 g/1OralNucare Pharmaceuticals, Inc.1996-11-11Not applicableUs
SucralfateTablet1 g/1OralLake Erie Medical Dba Quality Care Produts Llc1996-11-11Not applicableUs
SucralfateTablet1 g/1OralA-S Medication Solutions1996-11-11Not applicableUs50090 058220180913 8702 m5gre4
SucralfateTablet1 g/1OralA-S Medication Solutions1996-11-11Not applicableUs54569 444620180907 15195 15ioud2
SucralfateTablet1 g/1OralMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation2007-06-182012-10-31Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
International/Other Brands
Antepsin (Orion) / Sucramal (Menarini) / Sucraxol (Medifarma) / Ulcogant (Merck)
Categories
UNII
XX73205DH5
CAS number
54182-58-0
Weight
Average: 1448.682
Monoisotopic: 1447.588619666
Chemical Formula
C11H28Al8O51S8
InChI Key
MNQYNQBOVCBZIQ-JQOFMKNESA-A
InChI
InChI=1S/C11H20O35S8.8Al.16H2O/c12-47(13,14)36-1-3-4(41-49(18,19)20)5(42-50(21,22)23)6(43-51(24,25)26)9(38-3)39-11(2-37-48(15,16)17)8(45-53(30,31)32)7(44-52(27,28)29)10(40-11)46-54(33,34)35;;;;;;;;;;;;;;;;;;;;;;;;/h3-10H,1-2H2,(H,12,13,14)(H,15,16,17)(H,18,19,20)(H,21,22,23)(H,24,25,26)(H,27,28,29)(H,30,31,32)(H,33,34,35);;;;;;;;;16*1H2/q;8*+3;;;;;;;;;;;;;;;;/p-24/t3-,4-,5+,6-,7+,8+,9+,10-,11-;;;;;;;;;;;;;;;;;;;;;;;;/m1......................../s1
IUPAC Name
[({[(2S,3R,4S,5R,6R)-4,5-bis({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)-6-[({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)methyl]-2-{[(2R,3S,4S,5R)-3,4,5-tris({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)-2-[({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)methyl]oxolan-2-yl]oxy}oxan-3-yl]oxy}sulfonyl)oxy]alumanediol
SMILES
O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O

Pharmacology

Indication

The sucralfate suspension Label and tablet 15 are used for the treatment of active duodenal ulcer for up to 8 weeks. The tablet form may be used at a lower dose for healed duodenal ulcers, for the purpose of maintaining healing and preventing recurrence 13,15.

Sucralfate is also used in the prevention and/or treatment of gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia 2,13.

Associated Conditions
Pharmacodynamics

This drug aids in the healing of duodenal ulcers, relieving painful inflammation by creating a protective mechanical barrier between the lining or skin of the gastrointestinal tract and damaging substances 2. In addition, sucralfate acts to increase levels of growth factors locally, and also causes an increase in prostaglandins which are important in the healing of the mucosa (lining) of the gastrointestinal tract 2.

Mechanism of action

The mechanism of action of this drug in the healing duodenal ulcers is not yet completely defined, however, there are several probable mechanisms that adequately describe the healing activity of sucralfate. There is evidence that sucralfate acts locally to aid in tissue healing, and not systemically Label.

Studies in both humans and animals have indicated that sucralfate forms a complex that binds to protein-rich exudate found on the surface of ulcers. It binds to albumin and fibrinogen 7,8 preventing blood clot lysis by stomach acid (hydrochloric acid). Sucralfate increases the tissue levels of fibroblast growth factors and epidermal growth factors 6, leading to an increase in prostaglandins at the gastrointestinal tract lining, which promote the healing of gastrointestinal ulcers 2.

In the laboratory setting, a sucralfate-albumin film provides a barrier against the entry of hydrogen ions, which are a component of gastric acid. In humans, sucralfate, given at therapeutic doses for ulcers, decreases pepsin activity in gastric fluids by 32% Label. Pepsin has been shown to be damaging to tissues, further aggravating ulcer lesion inflammation 4. Bile salts have been implicated in mucosal injury to the gastrointestinal tract 9,10. Sucralfate has also been shown to adsorb bile salts in the laboratory, setting, which could further contribute to its beneficial effects in ulcer healing Label.

TargetActionsOrganism
APepsin
inhibitor
Humans
AFibroblast growth factor 2
agonist
inducer
Humans
APro-epidermal growth factor
inducer
Humans
UFibrinogen
binder
protector
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

This drug is absorbed from the gastrointestinal tract in very minimal quantities Label. The adsorbed sulfated disaccharide is excreted in the urine 13. This drug contains aluminum and after the administration of 1 g of sucralfate 4 times per day, about 0.001% to 0.017% of this aluminum content is absorbed in patients with normal renal function 13. This number is expected to increase in those with impaired renal function 13.

Volume of distribution

This drug is absorbed in a very small quantity, and normally localizes to inflamed gastrointestinal lesions Label.

Protein binding

Sucralfate is bound to plasma proteins, especially albumin and transferrin 13.

Metabolism

This drug is absorbed in very small quantities and is not significantly metabolized Label,13.

Route of elimination

The negligible amount of this drug that is absorbed is excreted mainly in the urine within 48 hours Label,16.

Half life

The half-life is not known. In animals, the elimination half-life of the sucrose component of this drug is from 6-20 h 16.

Clearance

Sucralfate contains aluminum. The administration of sucralfate in non-dialyzed chronic renal failure patients warrants careful consideration from the treating physician as the excretion of absorbed aluminum may be decreased, causing possible aluminum toxicity 13.

In dialyzed patients diagnosed with chronic renal failure, aluminum toxicity related to sucralfate has been observed and reported. The daily amount of aluminum ingestion (including sucralfate) should be carefully examined before administering sucralfate in combination with other drugs also containing aluminum, including various antacids 13.

Toxicity

Overdose

Overdosage has never been observed with sucralfate 13. It is unlikely, as administering a maximum dose of up to 12 g/kg/body weight in several animal species did not result in death. The lethal dose could not be determined in these studies 13. It is likely that overdose of sucralfate in humans would result in constipation, and supportive treatment would be advised 13.

Use in pregnancy

This drug is considered a pregnancy Category B drug. Studies have been performed in rodents and rabbits at doses up to 50 times the recommended human dose. No harm to the fetus has been observed in the abovementioned studies. Sufficient and well-controlled clinical trials have not been performed in pregnant women. Due to the fact that the results of animal studies are not always relevant to human response, sucralfate should be used during pregnancy only if it is deemed essential for the mother's health Label.

Use in nursing

Whether this drug is excreted in human milk is currently unknown. Many drugs are excreted in breast milk, therefore, if sucralfate is administered to a lactating and nursing woman, caution should be observed Label.

Carcinogenesis

24 month toxicity studies were performed in rodents, and the dose of sucralfate reached up to 1 g/kg (equivalent to 12 times the recommended human dose). No signs of sucralfate-related tumors were notedLabel.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe therapeutic efficacy of (R)-warfarin can be decreased when used in combination with Sucralfate.
(S)-WarfarinThe therapeutic efficacy of (S)-Warfarin can be decreased when used in combination with Sucralfate.
1alpha-Hydroxyvitamin D5The serum concentration of Sucralfate can be increased when it is combined with 1alpha-Hydroxyvitamin D5.
1alpha,24S-Dihydroxyvitamin D2The serum concentration of Sucralfate can be increased when it is combined with 1alpha,24S-Dihydroxyvitamin D2.
3-Aza-2,3-Dihydrogeranyl DiphosphateSucralfate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
4-hydroxycoumarinThe therapeutic efficacy of 4-hydroxycoumarin can be decreased when used in combination with Sucralfate.
AbacavirSucralfate may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbafunginSucralfate can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcarboseAcarbose may decrease the excretion rate of Sucralfate which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Sucralfate which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid alcohol.
  • Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
  • Take with a full glass of water.

References

Synthesis Reference

Nick V. Lazaridis, Moo K. Park, Yousry Sayed, "Method for preparing high potency sucralfate." U.S. Patent US4990610, issued March, 1973.

US4990610
General References
  1. Rees WD: Mechanisms of gastroduodenal protection by sucralfate. Am J Med. 1991 Aug 8;91(2A):58S-63S. [PubMed:1715673]
  2. Candelli M, Carloni E, Armuzzi A, Cammarota G, Ojetti V, Pignataro G, Santoliquido A, Pola R, Pola E, Gasbarrini G, Gasbarrini A: Role of sucralfate in gastrointestinal diseases. Panminerva Med. 2000 Mar;42(1):55-9. [PubMed:11019606]
  3. Lam SK: Why do ulcers heal with sucralfate? Scand J Gastroenterol Suppl. 1990;173:6-16. [PubMed:2190306]
  4. Bardhan KD, Strugala V, Dettmar PW: Reflux revisited: advancing the role of pepsin. Int J Otolaryngol. 2012;2012:646901. doi: 10.1155/2012/646901. Epub 2011 Nov 10. [PubMed:22242022]
  5. Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [PubMed:1957124]
  6. Korman MG, Bolin TD, Szabo S, Hunt RH, Marks IN, Glise H: Sucralfate: the Bangkok review. J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):412-5. [PubMed:7948825]
  7. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775]
  8. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP: Clot lysis by gastric juice: an in vitro study. Gut. 1989 Dec;30(12):1704-7. [PubMed:2612985]
  9. Gadacz TR, Zuidema GD: Bile acid composition in patients with and without symptoms of postoperative refulx gastritis. Am J Surg. 1978 Jan;135(1):48-52. [PubMed:341732]
  10. Duane WC, Wiegand DM: Mechanism by which bile salt disrupts the gastric mucosal barrier in the dog. J Clin Invest. 1980 Nov;66(5):1044-9. doi: 10.1172/JCI109932. [PubMed:7430343]
  11. FDA approval, Sucralfate suspension [Link]
  12. Sucralfate tablet FDA approval [Link]
  13. Product monograph, Sulcrate [File]
  14. MedSafe NZ, Sucralfate [File]
  15. Sucralfate FDA label, tablet form [File]
  16. Risk profile of sucralfate [File]
External Links
Human Metabolome Database
HMDB0014508
KEGG Compound
C07314
PubChem Compound
70789197
PubChem Substance
46508862
ChemSpider
26329506
ChEMBL
CHEMBL2029132
PharmGKB
PA451524
Wikipedia
Sucralfate
ATC Codes
A02BX02 — Sucralfate
AHFS Codes
  • 56:28.32 — Protectants
FDA label
Download (217 KB)
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentOesophagitis, Eosinophilic1
2Enrolling by InvitationSupportive CareGingivostomatitis / Hand, Foot and Mouth Disease (HFMD) / Herpangina1
3CompletedSupportive CareHead and Neck Carcinoma / Mucositis1
4CompletedTreatmentAntimicrobial Drug Susceptibility Pattern / Etiological Organisms / Stress Ulcer Prophylaxis / Ventilator-associated Bacterial Pneumonia1
4CompletedTreatmentChronic Erosive Gastritis1
4CompletedTreatmentChronic Radiation Proctitis1
4CompletedTreatmentIndigestion1
Not AvailableRecruitingDiagnosticNon-erosive Reflux Disease (NERD) / Reflux, Gastroesophageal1
Not AvailableWithdrawnDiagnosticGastro-esophageal Reflux Disease (GERD) / Indigestion / Non Erosive Reflux Disease1

Pharmacoeconomics

Manufacturers
  • Axcan pharma us inc
  • Nostrum laboratories inc
  • Teva pharmaceuticals usa inc
Packagers
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • A-S Medication Solutions LLC
  • Axcan Pharma Inc.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Caremark LLC
  • Dept Health Central Pharmacy
  • Direct Dispensing Inc.
  • Diversified Healthcare Services Inc.
  • Eon Labs
  • Giant Food Inc.
  • Golden State Medical Supply Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Ivax Pharmaceuticals
  • Levista Inc.
  • Long Wing International Inc.
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Merckle GmbH
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nostrum Laboratories Inc.
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Association
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Prasco Labs
  • Precision Dose Inc.
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Prime European Therapeuticals SPA
  • Qingdao Pana Life Biochem Co. Ltd.
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Sanofi-Aventis Inc.
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vangard Labs Inc.
  • Vistapharm Inc.
  • Warrick Pharmaceuticals Corp.
  • Watson Pharmaceuticals
  • Xactdose Inc.
Dosage forms
FormRouteStrength
TabletOral1000 mg
SuspensionOral1 g/10mL
TabletOral1 g/1
PowderNot applicable1 kg/1kg
SuspensionOral100 mg
SuspensionOral1 g
TabletOral1 g
Prices
Unit descriptionCostUnit
Sucralfate 1 gm/10ml Suspension 10ml Cup13.99USD cup
Carafate 1 gm tablet1.45USD tablet
Sucralfate 1 gm tablet0.72USD tablet
Sucralfate powder0.6USD g
Sulcrate 1 g Tablet0.59USD tablet
Apo-Sucralfate 1 g Tablet0.31USD tablet
Novo-Sucralate 1 g Tablet0.31USD tablet
Nu-Sucralfate 1 g Tablet0.31USD tablet
Pms-Sucralfate 1 g Tablet0.31USD tablet
Carafate 1 gm/10ml Suspension0.24USD ml
Sulcrate Suspension Plus 200 mg/ml Suspension0.11USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)>220https://www.trc-canada.com/product-detail/?S692350
water solubilityInsolublehttps://www.chemicalbook.com/ChemicalProductProperty_US_CB6239042.aspx
logP-7.087http://www.molbase.com/en/overview_54182-58-0-moldata-62765.html
pKa 0.43 to 1.19https://www.chemicalbook.com/ChemicalProductProperty_US_CB6239042.aspx
Predicted Properties
PropertyValueSource
Water Solubility0.714 mg/mLALOGPS
logP0.98ALOGPS
logP-5.6ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)13.53ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count35ChemAxon
Hydrogen Donor Count16ChemAxon
Polar Surface Area772.17 Å2ChemAxon
Rotatable Bond Count36ChemAxon
Refractivity175.09 m3·mol-1ChemAxon
Polarizability105.22 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7959
Blood Brain Barrier+0.8803
Caco-2 permeable-0.6433
P-glycoprotein substrateNon-substrate0.8087
P-glycoprotein inhibitor INon-inhibitor0.5656
P-glycoprotein inhibitor IINon-inhibitor0.986
Renal organic cation transporterNon-inhibitor0.8471
CYP450 2C9 substrateNon-substrate0.8611
CYP450 2D6 substrateNon-substrate0.8256
CYP450 3A4 substrateNon-substrate0.6233
CYP450 1A2 substrateNon-inhibitor0.772
CYP450 2C9 inhibitorNon-inhibitor0.8211
CYP450 2D6 inhibitorNon-inhibitor0.8865
CYP450 2C19 inhibitorNon-inhibitor0.7869
CYP450 3A4 inhibitorNon-inhibitor0.9828
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9328
Ames testNon AMES toxic0.5805
CarcinogenicityNon-carcinogens0.5356
BiodegradationNot ready biodegradable0.8432
Rat acute toxicity2.4219 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7937
hERG inhibition (predictor II)Non-inhibitor0.8793
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as disaccharide sulfates. These are disaccharides carrying one or more sulfate group on a sugar unit.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Disaccharide sulfates
Alternative Parents
O-glycosyl compounds / Ketals / Oxanes / Alkyl sulfates / Tetrahydrofurans / Oxacyclic compounds / Organic metal salts / Organic oxides / Hydrocarbon derivatives
Substituents
Disaccharide sulfate / Glycosyl compound / O-glycosyl compound / Ketal / Oxane / Alkyl sulfate / Organic sulfuric acid or derivatives / Tetrahydrofuran / Organic metal salt / Oxacycle
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

1. Pepsin
Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Jensen SL, Funch Jensen P: Role of sucralfate in peptic disease. Dig Dis. 1992;10(3):153-61. [PubMed:1611711]
  2. Hollander D, Tarnawski A: The protective and therapeutic mechanisms of sucralfate. Scand J Gastroenterol Suppl. 1990;173:1-5. [PubMed:2190304]
  3. Peterson WL: Pathogenesis and therapy of peptic ulcer disease. J Clin Gastroenterol. 1990;12 Suppl 2:S1-6. [PubMed:1978840]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
Inducer
General Function
Ligand-dependent nuclear receptor transcription coactivator activity
Specific Function
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name
FGF2
Uniprot ID
P09038
Uniprot Name
Fibroblast growth factor 2
Molecular Weight
30769.715 Da
References
  1. Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [PubMed:1957124]
  2. Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ: Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl. 1995;210:9-14. [PubMed:8578218]
  3. Szabo S, Kusstatscher S, Sakoulas G, Sandor Z, Vincze A, Jadus M: Growth factors: new 'endogenous drugs' for ulcer healing. Scand J Gastroenterol Suppl. 1995;210:15-8. [PubMed:8578198]
  4. Korman MG, Bolin TD, Szabo S, Hunt RH, Marks IN, Glise H: Sucralfate: the Bangkok review. J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):412-5. [PubMed:7948825]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inducer
General Function
Transmembrane receptor protein tyrosine kinase activator activity
Specific Function
EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in ...
Gene Name
EGF
Uniprot ID
P01133
Uniprot Name
Pro-epidermal growth factor
Molecular Weight
133993.12 Da
References
  1. Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ: Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl. 1995;210:9-14. [PubMed:8578218]
  2. Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [PubMed:1957124]
  3. Konturek SJ: Role of growth factors in gastroduodenal protection and healing of peptic ulcers. Gastroenterol Clin North Am. 1990 Mar;19(1):41-65. [PubMed:1970337]
4. Fibrinogen
Kind
Group
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
Protector
This group includes the fibrinogen alpha chain, beta chain, and gamma chain.
References
  1. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775]
  2. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP: Clot lysis by gastric juice: an in vitro study. Gut. 1989 Dec;30(12):1704-7. [PubMed:2612985]
  3. Sucralfate - Drug Summary [Link]

Drug created on June 13, 2005 07:24 / Updated on July 21, 2019 06:23